4.7 Article

A Gastroenterologist's Guide to Probiotics

Journal

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 10, Issue 9, Pages 960-968

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2012.03.024

Keywords

Clostridium difficile; IBD; IBS; Crohn's Disease and Colitis; Yogurt; Pouchitis

Funding

  1. VSL Pharmaceuticals, Inc.
  2. NIH [DK089016]

Ask authors/readers for more resources

The enteric microbiota contribute to gastrointestinal health, and their disruption has been associated with many disease states. Some patients consume probiotic products in attempts to manipulate the intestinal microbiota for health benefit. It is important for gastroenterologists to improve their understanding of the mechanisms of probiotics and the evidence that support their use in practice. Clinical trials have assessed the therapeutic effects of probiotic agents for several disorders, including antibiotic-or Clostridium difficile-associated diarrhea, irritable bowel syndrome, and the inflammatory bowel diseases. Although probiotic research is a rapidly evolving field, there are sufficient data to justify a trial of probiotics for treatment or prevention of some of these conditions. However, the capacity of probiotics to modify disease symptoms is likely to be modest and varies among probiotic strains-not all probiotics are right for all diseases. The current review provides condition-specific rationale for using probiotic therapy and literature-based recommendations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available